BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is one of the most common cancer-
related causes of death worldwide. In light of the very poor 5-year-survival new therapeutic …

AIM: To examine the underlying mechanisms of erlotinib-induced growth inhibition in
hepatocellular carcinoma (HCC). METHODS: Erlotinib-induced alterations in gene …

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is one of the most common cancer-
related causes of death worldwide. Due to very poor 5-year-survival new therapeutic …

BACKGROUND. Growth factor overexpression, including epidermal growth factor receptor
(EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine …

Purpose Epidermal growth factor receptor/human epidermal growth factor receptor 1
(EGFR/HER1) and ligand expression is frequently seen in hepatocellular cancers (HCCs) …

Erlotinib is a small-molecular inhibitor of epidermal growth factor receptor (EGFR). Here, we
identify that cancerous inhibitor of protein phosphatase 2A (CIP2A) is a major determinant …

Hepatocellular carcinoma (HCC) is associated with a poor prognosis due to late diagnoses
and a lack of effective treatment options. Epidermal growth factor receptor (EGFR)–targeted …

Background Epidermal growth factor receptor (EGFR) has emerged as an important
therapeutic target. Overexpression of EGFR is frequently observed in hepatocellular …

Epidermal growth factor receptor (EGFR) is overexpressed in a significant proportion of
hepatocellular carcinomas. Recent studies of EGFR inhibitors to treat hepatocellular …

Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or
Renal Dysfunction: CALGB 60101 Page 1 Phase I and Pharmacokinetic Study of Erlotinib for …